KT-253
kymera therapeutics
['leukemia', 'kymera ']
kymera therapeutics presents data demonstrating superior efficacy of kt-253, a potent and selective heterobifunctional mdm2 degrader, compared to small molecule inhibitor in preclinical leukemia models at the european hematology association congress via 
Fan of #TechBio with #AI, #ML and #Automation, #Genetics with #CRISPR, #CellEngineering with #SynBio and #iPSC, #Immunology and #Oncology with #TPD and #Kinome.